KKR, a prominent investment firm, has announced its acquisition of Immedica Pharma, a Stockholm-headquartered pharmaceutical company dedicated to commercializing medicines for rare diseases and specialty care products. This acquisition will include the reinvestment of Impilo, the current owner of Immedica, which will result in their equal ownership alongside KKR.
KKR and Impilo will collaborate with Immedica’s management team to facilitate the company’s continued expansion, including the launch of their recently approved ultra-orphan drug, Loargys, the development of additional pipeline assets, and continued in-licensing and mergers and acquisitions. Immedica is also considering expansion into the United States, subject to regulatory approval of Loargys by the U.S. Food and Drug Administration (FDA).
Founded in 2018 by Impilo, Immedica Pharma has established a robust portfolio and pipeline of treatments, primarily in hematology and oncology as well as genetic and metabolic diseases for rare conditions with significant unmet medical needs. The company has quickly emerged as a leader in the European rare disease space, generating revenues of EUR 100 million and experiencing annual growth of over 50%.
Anders Edvell, CEO of Immedica, expressed his enthusiasm for continuing the partnership with Impilo and welcoming KKR as a strategic partner for the next phase of Immedica’s journey. KKR’s investment in Immedica is being made through its KKR Health Care Strategic Growth Fund II, valued at $4.0 billion and dedicated to investing in high-growth healthcare companies.
